In this retrosp ective clinical trial, we evaluated the effectiveness of low-dose oral methot rexate in the mana gement of bilat era l Meni ere 's disea se of inunu ne-med iat ed origin. A t our ter tiarycare ref erral center, we eva luated ten men and eight wome n who had longstanding bilateral Meniere 's disease that had been unresponsive to traditional conse rvative medical management. Sixteen ofthese patients had steroid-respons ive bilateral Men iere 's disease. Two patients had contraindica tions to ste roids, but their clinical and lab oratory eva luations were cons istent with an immune-tnediated p rocess.
Abstract
In this retrosp ective clinical trial, we evaluated the effectiveness of low-dose oral methot rexate in the mana gement of bilat era l Meni ere 's disea se of inunu ne-med iat ed origin. A t our ter tiarycare ref erral center, we eva luated ten men and eight wome n who had longstanding bilateral Meniere 's disease that had been unresponsive to traditional conse rvative medical management. Sixteen ofthese patients had steroid-respons ive bilateral Men iere 's disease. Two patients had contraindica tions to ste roids, but their clinical and lab oratory eva luations were cons istent with an immune-tnediated p rocess.
Patients we re treat ed with 7.5 to 20 mg/w eek of o ral niethotrexate. Th e tnean duration of treatmeilt was 16.7 months (ran ge: 8 to 35) , with a inean fo llowup of2 ye ars (ra nge: 9 mo to 5 yr). Chan ges in clinical symp toms (vatigo, hearing loss, tinnitus, and aura lfullness) , audiometric changes, and side effects of therapy were eva luated.
Vatiga resol ved in 14 pa tients (78%), was subs tantially all eviat ed in three pat ients (17%), and remained unehanged in one patient (6%). Hea ring improved infi ve pati ent s (28%) and stab ilized in seven patients (39%). Tinn itus and au ralfu llness resol ved or was relieved in II of 17 (65%) and 13 of 14 (93%) patients, resp ecti vely. Side effects we re minima l and reversible . We cone lude that low-dose oral m ethotrexate is effective and safe f or treating bi latera l Me niere 's disease of immune-m ediated origin. In this study, meth otrexate alleviated vertiginous symp toms and improved 01' stabilize d hearing in most patients. Low-dose meth otrexate can be cons idered for patient s with imtnune-me diated bilat eral Introduction Bilateral Menieres disea se is an uncommon entity that presents a man agement dilemma to the otolog ist. Conservative manage ment of bilateral Meniere' s disea se ineludes a lo w -salt die t, di ur eti cs , a nd ve stib ul ar suppressa nts. Patients in whom this treatment fails have few othe r options. Traditional surgical pracedures for unilateral Me niere ' s disease are not app licable for patients with bilateral disease. Systemic streptomycin, although beneficial, is assoc iated with a high incidenee of ataxia and oscillopsia .!" Oral stera ids and/or cyc1ophosphamide are effec tive for a significant numb er of patient s with immune-media ted bilateral Meni ere ' s disease, but their side effects increase in incid enee and severity with long-term use, and not all patient s tolerate thern. " Meth otrexate has been used effectively in the treatment of a bra ad spec trum of rheum atic diseases." ? Low-dose meth otrexate is the drug of choice in the long-term manage ment of rheum atoid arthri tis.?It has been reported that methotrexa te is effective in treating coc hleo vestibular disorders of immune-medi ated origin .'"! '
In this study, we report our exp erience in managing bilateral Meniere' s disease of imm une-me diated orig in with low doses of aral metho trexate .
Materials and methods
Patient selection and evaluation. Th is retro spective study evaluated the outcomes of 18 consecutively presenting patient s with bilateral Men iere ' s disease of immunemediated etio log y who were trea ted with meth otrexate. All patien ts had a longstandin g history of bilateral Meniere ' s disease that had failed to respond to a low-salt diet and diu ret ic therap y.
The diagnosis of stero id-responsive bilateral Men iere' s disease was based on three criteria: I) a history of episodi c were instructed to abstain from alcohol to decrease the risk of liver complications, and women of childbearing age were informed that methotrexate is a teratogen and can terminate pregnancy.
Control of symptoms.
A minimum of 6 to 8 weeks of therapy is required to assess the response to methotrexate therapy .11 All patients in this study received a minimum of 6 months' therapy. Vertigo wasjudged to beeitherresolved (completely absent) , substantially improved (severity and frequency of attacks had decreased to the point that vertigo was no longer disabling), or unchanged. Hearing improvement after methotrexate therapy was defined as an increase of more than 10 dB in pure-tone average (at 0.5, I, 2, and 4 kHz) and/or a 15% improvement in speech discrimination score. Tinnitus and aural fullness were recorded before, during, and after treatment and were reported as either resolved, improved, unchanged, or worse,
Results
The mean age of the 18 patients (10 men) in this study was 57 years (range: 36 to 77). The mean duration of symptoms prior to the initiation of methotrexate was 10 years (range: 1 to 45). The mean duration of methotrexate treatment was 16.7 months (range: 8 to 35), and the mean followup was 2 years (range: 9 mo to S yr). Sixteen patients reported that vertigo was their most disabling symptom. The other two patients said that tinnitus and hearing loss were their main complaints, although both had occasional debilitating vertigo . Ten patients had other medical probiems, including arthritis, diabetes , gout , idiopathic retinopathy , monoclonal gammopathy, and Reiter' s syndrome (table I) vertigo , bilateral fluctuating hearing loss, tinnitus, and aural fullness , 2) audiometric evidence of bilateral hearing loss (electronystagmography and electrocochleography were used in selected cases to support the clinical diagnosis), and 3) a diagnostic course of oral predni sone (I mg/kg/day) for 2 to 4 weeks (prednisone test) .
Sixteen patients had a positive prednisone test. A positive result was defined as I) the elimination or marked alleviation of vertiginous symptoms, tinnitus , and aural fullness, 2) an improvement in pure-tone average (at 0.5, I, 2, and 4 kHz) of more than 10 dB, and/or 3) a 15% increase in speech discrimination score . One patient with diabetes mellitus and another who had previously developed a rash while taking predni sone were started on methotrexate without a trial of steroids . Both of these patients had clinical histories and laboratory tests suggestive of an immune-mediated proces s.
Four patients had previously undergone surgery (two vestibular neurectomies, one endolymphatic sae drainage , and one labyrinthectomy) for incapacitating vertigo at other institutions. Two of these patients developed a profound hearing loss after surgery ..
All patients underwent a metabolic workup , which consisted of a complete blood count with differential (CBC), a measurement of the erythrocyte sedimentation rate (ESR ), a sequential multiple analysis of 20 serum .chemical constituents, a fluorescent treponemal antibody absorption test, a determination of antinuclear antibody titers (ANA) , a measurement of rheumatoid factor, and a urinalysis . A Western blot test for the detection of antibodie s to inner ear antigen s was obtained in eight patients. Liver enzyme levels and CBCs were monitored every 4 to 8 weeks during treatment.
Pure-tone average and speech discrimination were assessed every 2 to 3 months after the initiation oftreatment: Followup audiologic evaluations were obtained every 6 to 12 months after the completion of treatment. Each patient's most recent audiogram was compared with his or her baseline audiogram.
Appropriate imaging studies (to rule out retrocochlear . lesions) and baseline chest x-rays were obtained prior to the initiation of methotrexate.
Treatment. All patients were evaluated by a rheumatologist-immunologist prior to treatment, and they were followed at 4-to 8-week intervals throughout their treatment course. Our treatment protocol was identical to the regimen used to treat rheumatoid arthritis.? Oral methotrexate was started at a dose of 7.5 mg/week and was increased progressively to 12.5 to IS mg/week. The minimum dose necessary to achieve optimum control of symptoms was used. The highest dose administered was 20 mg/week (two patients). All patients continued on a low-salt diet, a potassium-sparing diuretic (hydrochlorothiazide-triamterene), and I mg/day of folic acid to minimize complications such as stomatitis." All patients The detai led data regarding the otologie and audiologie evaluations before and after methotrexate treatment are presented in table 3 . Vertigo resolved in 14 patients (78%), was substantially eontrolled in three patients ( 17%), and remained unehanged in one patient (6%).
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Hearing imp roved in five patients (28%), worsened in four (22%), and stabilized in seven (39%) . Th e other two patients (11 %) experieneed improved hearing in one ea r and poorer hearing in the other.
Of the 17 patients who had experieneed tin nitus, the eo nditio n resolved in one (6%), was alleviated in 10 (59 %), remained unehanged in five (29%), and worsened in one (6%) . Tinnitus was not a signifieant com plaint in one patient.
Of the 14 patients who had experienee d aura I fullness , the eondi tio n resolved in six patie nts (43 %), was allevi-ated in se ven (50 %), and wor sened in one (7%). It was not a signifieant complaint in fo ur patients.
No patient developed any serious side effeets throughout the eo urse of treatment. The mo st common side effeet was mild nau sea on the day of treatment (table 4) . Two patients developed severe nau sea, whieh resolved when they were switehed from oral administration to intramuseular injeetions. Other side effeets included fatigue, dia rrhea , hives, and mildalopeeia, all ofwhieh were transie nt and did not interfere with the treatment or outeome.
Discussion
Immune-mediated proeesses have been imp liea ted in the pathogenesis of Meniere' s disease ever sinee Mcf. abe first deseribed autoi mm une senso rineura l hear ing loss in his landma rk paper in 1979 . 13 Hug hes et al reported that Non surgical treatments of bilateral Meniere's disease incl ude aminoglycoside infusion into the middle ear , intramuscular stre ptomycin, and oral corticosteroids andi or cyclophosphamide (for dise ase of immune-mediated origin). Because of the risk of hearing loss, however, man y oto logi sts are reluctant to use an aminoglycoside in patients with bilateral disease .' Intratympanic gentamicin injection in the most active ear is an effective approach for managi ng vertigo when the most active ear can be identified."
In 1948, Fowler reported the firs t docum ented use of streptomycin for the treatment of bil ateral Me niere's disease, and this dru g is still considered the treatment of choice.' Hum an and animal studies have show n that strep tomycin is tox ic to the erista of the semici rcular ca nals and ca n produce a chemical ablation of the ves tibular system and preserve hearing.' Side effects include perioral numbness and tingling, severe nausea, skin rash , and oscillopsia.' In 1980, Wi lso n and Schuknecht published the largest series of pat ients trea ted wi th ablative streptomycin therapy; they reported a complete resolution of vertigo in 19 of their 20 patients. 5 However, during treatment, all patients developed severe ataxia that did not resolve for 2 to 9 months. Wilson and Schuknecht reparted that during 16 years of followup, three patients had per sistent mild ataxia, four were unab le to walk in the dark, and three had per sistent oscillopsia.' In a metaana lysis publis hed in 1990, Langman et al reviewed 12 studies documenting the outcomes of 107 patients who had been treated with ablative or titration stre ptomycin therapy .I Relief of vertigo was see n in 50 to 100% of patients who received ablative treatment and in 63 to 100% of patients wh o received titration therapy. Persistent disequilibr ium , however, was noted in up to 64% of patients, regardless of whether they received ablative or titration therapy. Althou gh strep tomyc in therapy is successful in co ntro lli ng ver tiga, it mu st be administe red carefully to minimize associated mor bidity .
Steraids and cyclophosphamide are the traditional medical treatments for immune-mediated coc hleovestibular disorders , incl ud ing bilateral Meniere' s disease. Plasmapheresis has also been recommended, but it is expensive and not universaily effective." The dur ation of steraid or cyclophosphamide therapy should be individualized according to treatmentresponse and drug tolerance." Symptom s can recur when immunosuppressive treatment is discontinued earl y. T he National Institutes of Health have recommended treating autoimmune vasc ulitis, such as Wegener' s granulomatosis and Cog an 's syndrome, with im munos uppressive treatment for 1 year after the disappearance of active disease." :" A simi lar duration of treatment has bee n suggested for irnmune-mediated otolog ic disorders." Prola nged administration of steroids and/or cyclophosphamide has bee n assoc iated with serious and sometimes life-threatening adverse reac tio ns (table 5) . 88 ENT·Ear, Nose & Throat Journal' February 2000
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In eontrolled elinieal trials in seasonal allergie rhinitis patients using the reeommended dose, the incidenee of headaehe (12%), somnolenee (8%), fatigue (4%),
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and dry mouth (3%) with e LA RIT IN-was similar to that of plaeebo (11%, 6%, 3%, and 2%, respeetively).
-T he incidenee of sedation with CLARITl -(8%) was similar 10mg (IOlr~+~rJ"ne~\ to that ofplaeebo (6%) at the reeommended dose.
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n studies with CLARITI -at doses 2 to 4 times higher than the reeommended dose of 10 mg, a dose-related inerease in the incidenee of somnolenee was observed.
Experience Counts. In add ltion,thefollowing spontaneousadverse eventshave beenreportedrarel y during the marketingof loratadine: abnormal hepati e funetion, ineluding jaundiee, hepati tis, and hepati e necrosis; alopeeia; anaphylaxis; breast enlargement; erythemamultiforme;peripheral edema; and seizures. OVERDOSAGE: In adul ts, somnolenee, taehyeardia, and headaehe have beenreportedwith overdoses greater than10mgwith theTabl et form ulat ion (40to 180 mg). Extrapyramidal signsand palpitations have been reported in ehildren with overdoses of great er than 10 mgof CLARITIN Syrup. In theevent of overdosage, general symptomatie and supportive measures should be instituted promptlyand maintained for aslong asneeessary.
Treatment of overdosage would reasonably eonsist of emesis (ipeeae syrup), exeept in patients with impaired eonseiousness, followed by the administration of aet ivated ehareoal to absorb any remaining drug. If vomi ting is unsueeessful, or eontraindieated, gastrie lavage should be perf ormed with normal sal ine. Saline eatharties may also be of value for rapid diluti on of bowel contents. Lor atadine is not elimi nated by hemodialysis. It is not known if loratadine is eliminated by peritoneal dialysis.
Nodeathsoeeurred at oral doses up to 5000 mg/kg in rats and miee (greater than2400 and 1200 times, respeeti vel y, the maximum reeommended humandail y eral dose on a mg/m' basis). Single oral doses of loratadi ne showed no etteets in rats, miee, and monkeys at doses ashighas10times themaximum reeommended human daily oral doseona mg/m' basis.
Adverse events reported in plaeebo-eontrolled ehronieidiopathie urtiearia trials were similar to those reported in allergie rhinitis studies.
Adverse event rates did not appear to ditter signifiea ntly based on age, sex, or race, although the numberof nonwhite subjeets was relatively small. CLARITIN REDlTABS (Iorat adine rapidly-disinlegraling tablets): Approximately 500 patient s reeeivedCLARITINREDlTABS(loratadlne rapidly-disintegrating tablets) in eontrol led elinieal trial s of 2 weeks' duration. Inthese studies, adverse eventsweresimilar in type andfrequeney to those seen with CLAR ITINTablets and plaeebo.
Administration of CLARITIN REDlTABS(Ioratadinerapidly-disintegr ating tablets) did not resultin aninerease d reportingfrequeney of mouth or tongueirritation.
CLARITIN Syrup: Approximate ly 300 pedlatrie patients 6 to 12 years of age reeeived 10 mglorat adine once daily in eontrolled elinieal trials for a period of 8-1 5 days. Among these, 188 ehildren were treated with 10 mg loratadine syrup onee dai ly in plaeebo-eontrolled trial s. Adverse events in these pediatrie patientswere observed to oeeur with type andfrequeney similar to those seen in the adult populat ion, The rate of premature diseont inuanee dueto adverse events among pediatrie palients receivingloratadine10 mg daily was less than1%. +307% +73% There does not appear to be an inerease in adverse events in subjeets who reeeivedoral eontraeeptives and loratad ine.
Careinogenesis, Mutagenesis, and Impairment of Fertility: In an 18-month earei nogenieity study in miee and a 2-year studyin rats, loratadine was administered in the diet at doses up to 40 mg/kg (mice) and25mg/kg (rats). In the earei nogenieity studies, pharmaeokinet ieassessments were earried outto determine animal exposu reto the drug. AUCdata demonstrat ed that theexposure of miee given 40 mg/kg of loratadine was 3.6 (Ioratadine) and 18 (desearboethoxyloratad ine) times hi gher than in humans given the maximum reeommended daily oral dose. Exposure of rats given 25 mg/kg of loratad ine was 28 (Ioratadine) and 67 (desearboethoxyloratadine) times higher than inhumans given the maximum reeommended daily oral dose. Malemiee given 40 mg/kg hada signifieantly higher incidenee of hepatoeellulartumors (eombined adenomas andeareinomas) than eoneu rrent controis. In rats, a signifieantly higher incidenee of hepatoeell ul ar tumors (eom bined adenomas and earei nomas) was observed in males given 10 mg/kg and malesand females given 25 mg/kg . The elinieal signifieanee of these findings during long-term use 01 CLARITIN is not known.
In mutageni eity studies, there was no evidenee of mut agenie potential in reverse (Ames) or forwardpoi nt mutation(CHO-HGPRT) assavs, or in theassay for DNA damage (rat pnrnarynepat ocvt e unseheduled DNA assay) or in two assays for ehromosomal aberrations (human peripheral blood Iymphoeyte clastogenesis assay and the mouse bone marrow eryt hroeyte mieronueleus assay). In the mouse Iymphoma assay, a positive finding oeeurred in the nonaeti vated but not the aetivated phaseofthestudy.
Deereased fertilityin mal e rats, shown by lowerfemaleeoneeption rates, oeeurred atanoral dose of 64 mg/kg (approximately 50 times the maximum reeommended human daily oral dose on a mg/m' basis) and was reversible with eessation of dosingo Loratadine had no etteet on mal e or lemale fert ility or reproduction in therat at an oraldose of approximateV 24 mg/kg (approximately 20times the maximum reeommendedhuman daily eral doseon a mg/m basis).
Pregnaney Category B: There was no evidenee 01ani mal teratogenieity in studies performed in rats and rabbi ts atoral doses up to 96 mg/kg (approximately 75 times and 150times, respeetivel y, themaximumreeommendedhumandai ly oral dose on a mg/m' basis). Thereare, however, noadequate and well-eontrol led studiesin pregnant women. Beeause ani malreproductionstudies are not always predietive of human response, CLARITIN should be used during pregnaney only if elearly needed.
Nursing Mothers: Loratadineand its metabolite, desearboethoxyloratadine, pass easily into breast milkand achieve eoneentrat ionsthat are equivalent to plasma level s with an AUCmillJAUC,'asma ratio of 1.1 7 and 0.85 for loratadine and descarboethoxyloratadine, respeetively. Following a single oral dose of 40 mg, a small amount of loratadine and desearboethoxyloratadinewas exereted into the breast milk (approximately 0.03% of 40 mgover 48 hours). A deeisionshould be made whether to diseont inuenur sing or to diseontinuethedrug, taking into aeeount the importanee of the drugto the mother. Cautionshould be exereised when CLARITINis administered to a nursi ng woman.
Pediatrie Use: The safety of CLARITI NSyrup at a dail y dose of 10mg has beendemonstratedin 188 pediatrie patients 6-12 years of age in plaeebo-eontroll ed 2-week trials. The etteetiveness of CLARITINforthe treatmentof seasonal allergie rhi nitis and ehronie idi opathie urti eari a in this pediatrieage group is based on an extrapolation of the demonstrated effieaey of CLARITINin adu lts in theseeonditionsand thelikelihood that the disease eourse, pat hophysiology, and the drug's etteet aresubstantiallysimilar to that of theadults. The reeommendeddose forthe pediatrie population is based on eross-studyeomparison of thepharmaeokineties of CLARITIN in adultsand pediatrie subjeets and on thesafety profil e of loratadine in bot h adultsandpediatrie pati ents at doses equal to or higherthanthereeommendeddoses. The safety and etteetiveness of CLARITIN in pediatrie patient s under 6 years01 agehavenot beenestablished. ADVERSE REACTIDNS: CLARITIN Tablets: Approximately 90, 000 patient s, aged 12 and older, reeeived CLARITIN Tabl ets 10 mg onee daily in eontrolled and uneontrolled studies. Plaeeboeontrolled elinieal trials at the reeommended dose of 10 mg onee a day varied from 2 weeks' to 6 months' durat ion. The rate of premature withdrawal from these trials was approximately 2% in both thetreatedand plaeebo groups. REPORTED Side effeets. In an effort to treat immune-mediated otologic disorders with a less toxic immunosuppressive agent that could be administered for a prolonged period, we began using low-dose oral methotrexate in 1991. This medication was found to be safe and effective. 10 .1 I Methotrexate ha s been widely used in the treatment of rheumatologic diseases, and it has revolutionized the treatment of rheumatoid arthritis. ' Methotrexate is an antimetabolite that inhibits dihydrofolate reductase and interferes with DNA synthesis, repair, and replication.
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Despite its effectiveness, the mechanism of methotrexate action in chronic inflammation and immune-mediated disease remains unclear. v -" Weekly low-dose (7.5 to 25 mg) methotrexate has shown favorable results in adult and juvenile rheumatoid arthritis , corticosteroid-dependent asthma, inflammatory bowel disease, inflammatory myopathy, and inflammatory eye diseases. v":" In the past decade, methotrexate has replaced nonsteroidal antiinflammatory drugs as the treatment of choice for adult rheumatoid arthritis. ? Long-term (>84 mo) prospective studies showed that the elinical response was sustained and the incidenee of side effects was acceptable .l-"
Adverse reaetions to methotrexate are completely different when it is taken at a low dose (7.5 to 25 mg/wk) than when it is taken in the high doses that are used in cancer chemotherapy (100 to 1,000 mg/rn?body-surface area per cycle).?Nausea, anorexia, stomatitis, and diarrhea are the most common side effects, but dizziness, headache, mood .alterations, and fatigue can also occur. Many of these adverse reaetions can be diminished by supplemental folic acid ther apy (I mg/day) ,""?Methotrexate is a teratogen that also induees abortion, so of cour se it should not be prescribed for pregnant women.? Low-dose methotrexate has exhibited no carcinogenic effeet to date." Serious complications inelude hepatotoxicity and cirrhosis. The risk of hepatotoxicity in rheumatoid arthritis has beenestimated to be less than I per 1,000 cases after 5 years of treatrnent." These risks are further minimized when small doses are used in a pulse fashion on a regular schedule.? AIcohol use, morbid obesity, glucose intolerance, and type 1 (insulin-dependent) diabetes are risk factors for hepatotoxicity. Rare complications of methotrexate therapy inelude nephrotoxicity, interstitial pneumonitis, hypersensiti vity reaetions, and reversible myelosuppres-sion. 39 Liver function tests shouId be monitored every 4 to 8 weeks while patients areon treatment, and drug doses should be adjusted accordingly. Routine liver biopsies are not necessary as long as liver function remains norrnal ." A prospective study of230 rheumatoid arthritis patients found that only 8% discontinued treatment because of complications."
The results of this study indicate that low-dose oral methotrexate is effective in the management of immunemediated bilateral Menieres disease. A minimum of 6 weeks of therapy is required before a response is seen. Vertigo resolved or was alleviated in 94% of our patients, and hearing improved or remained stable in 67%. In patients with significant tinnitus and aural fullness , these symptoms diminished or resolved in 65 and 93%, respectively. These results compare favorably with those seen with streptomycin, steroid, and cyelophosphamide treatment. Methotrexate was generally well tolerated by our patients, and side effects were rnild and reversible. The use ofmethotrexate avoids the morbidity associated with streptomycin therapyand offers a viable ' alternative to 91 KILPATRICK, SISMANIS, SPENCER , W ISE steroids and/or cyclophosphamide, particularly when longterm treatment is required and/or when othe r immuno suppressant medications are contraindicated.
Althou gh am result s are encouraging, we acknowledge that this open c1inical trial did not include a placeba control group. However, the possibility of spontaneous impro vement in symptoms in patient s with longstanding bilateral Meniere's disea se is very unIikely. A prospective, randomized, multi-institutional study is needed to fully evaluate the efficacy of methotrexate and to compare it with other therapies for bilateral Meniere' s disease.
In conclusian, the experience gained from this study suggests that 1) low-dose oral methotrexate is a safe and effective treatment for immune-rnediated bi lateral Meniere's disease, and provides good control of vertigo and stabi lization of hearing in most patients , 2) methotrexate is generally weil tolerated, with an acceptable incidenee of side effect s, and 3) methotrexate shou ld be considered when long-term treatment is required or when steroids and/or cyclophosphamide are contraindicated.
